Trials / Completed
CompletedNCT04812795
Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2,214 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
Project RESIST is an R01 study funded by NCI focused on determining the effects of using culturally tailored inoculation approaches to increase resilience to tobacco marketing influences among young adult sexual minority women ages 18-30 and incorporates critical stakeholder inputs that support later adoption and implementation. The study team is utilizing formative research to design and pre-test anti-smoking messages and two national longitudinal online survey experiments.
Detailed description
This study will recruit 2000 young adult sexual minority women (SMW), ages 18-30 years, current smokers (n = 1000) and not current smokers (n=1000). The study team will randomly assign participants to a condition in which they will be exposed to either culturally tailored anti-smoking messages or non-tailored. Participants will receive these messages at baseline and 1, 2, and 3 weeks post baseline. They will be asked to complete a follow-up survey one month post baseline. Intentions to quit smoking as well as intention (among current smokers) and intention to purchase cigarettes (among current nonsmokers) will be measured at baseline and one-month post baseline.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Culturally tailored anti-smoking messages | Anti-smoking messages that are culturally tailored for sexual minority women. |
| OTHER | Non-culturally tailored interventions | Anti-smoking messages that are not culturally tailored for sexual minority women. |
Timeline
- Start date
- 2021-09-08
- Primary completion
- 2022-05-05
- Completion
- 2022-06-20
- First posted
- 2021-03-24
- Last updated
- 2023-11-15
- Results posted
- 2023-08-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04812795. Inclusion in this directory is not an endorsement.